



ASX Release

Anatara announces departure of Tracey Mynott to pursue humanitarian applications

BRISBANE, 28 August 2018: Anatara Lifesciences (ASX:ANR) announces the departure of Dr Tracey Mynott, Chief Scientific Officer.

Tracey is a co-founder of Anatara and an inventor of Anatara's Detach technology. She led the development of Detach including the successful pig field trials which were required for submission to the Australian Pesticides and Veterinary Medicines Authority (APVMA) for marketing approval. Tracey also played a critical role in the exclusive global licensing of the technology to Zoetis Inc, which was announced on May 15, 2018.

After conducting a thorough review of potential opportunities in human gastrointestinal health, Anatara has made the commercial decision to focus on the development of a multi-component product aimed at promoting gut health and managing the symptoms associated with gastrointestinal disorders such as Inflammatory Bowel Disease and Irritable Bowel Syndrome.

Following the successful development of Detach, Tracey has made the decision to leave Anatara to pursue her long-standing passion to develop the technology to control infectious diarrhoea in developing countries. Diarrhoea is the second leading cause of death in children in the developing world, killing almost one million children each year. Infectious diarrhoea also poses a major risk for travellers visiting developing countries and during times of major natural disasters.

Anatara will license the intellectual property necessary for the development of products to treat infectious diarrhoea in the developing world to Tracey. Anatara will receive a share in any commercial returns from successful development.

Tracey will continue to act as a consultant to Anatara.

“Tracey is a co-founder of Anatara and the successful development and licensing of Detach is a direct result of her persistence and dedication. We are indebted to Tracey for her contribution to the Company and wish her every success in the pursuit of her long-standing ambition to alleviate infectious diarrhoea in the developing world” said Dr Jay Hetzel, Chairman.



Dr Tracey Mynott commented, “I am proud that we achieved what we set out to do with Detach. We could not have hoped for a better partner than Zoetis to get Detach on the market”.

“My goal has always been to see the technology used in the developing world and now is the right time for me to do that. Anti-microbial resistance has a disproportionate negative impact on childhood health in the developing world and provides major challenges for childhood health initiatives, that I believe I can help address. I wish Anatara success as it moves down its path in Inflammatory Bowel Disease and Irritable Bowel Syndrome” said Dr Tracey Mynott.

For more information please contact:

Investor inquiries	Media inquiries
Dr Jay Hetzel, Chairman Anatara Lifesciences +61 (0) 7 3394 8202 jhetzel@anatara.com	Jane Lowe IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

About Anatara Lifesciences

Anatara Lifesciences (ASX: ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anatara granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anatara is now focused on developing its human product pipeline for gastrointestinal health applications. For more information, please visit www.anataralifesciences.com.

For personal use only